Kornimate/medical-research-clean huggingface dataset:
clinical study of venetoclax combined with azacytiside in the treatment of myelodysplastic/myeloproliferative neoplasms in adults

Conditions: Myelodysplastic/Myeloproliferative Neoplasms; Adult

Summary: to explore the efficacy of venetoclax combined with azacytidine in myelodysplastic / myeloproliferative neoplasms（mds/mpn）, so as to improve the overall survival and treatment status of mds/mpn patients.

at present, there is no standardized treatment strategy for mds/mpn. the purpose of our study is to explore the efficacy of venetoclax combined with azacytidine in the treatment of mds/mpn, so as to improve the overall survival and treatment status of patients with mds/mpn. after the participants were treated with four cycles of venetoclax combined with azacytidine, the efficacy was evaluated according to the 2015 adult mds/mpn response criteria to determine the disease status. participants with disease progression and intolerance withdrew from the study during treatment.

Eligibility criteria:
inclusion criteria: 1. male or female, age (years) \>= 18； 2. patients newly diagnosed or previously treated with mds/mpns (cmml, mds/mpn-u, acml) according to 2016 who diagnostic criteria: initial diagnosis: cmml: cpss-mol intermediate risk 2 and above; acml; mds/mpn-u. previous treatment: hma treatment failed. 3. eastern cooperative oncology group (ecog) performance status of 0,1, 2 ; 4. liver function: total bilirubin ≤3 upper limit of normal (uln); aspartate aminotransferase (ast) ≤3 uln; alanine aminotransferase (alt)≤3 uln； 5. renal function#ccr ≥30 ml/min; 6. patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent. exclusion criteria: 1. acute myeloid leukemia 2. myelodysplastic syndrome 3. subjects who had previously been treated with venetoclax 4. subjects who are known to be allergic to ingredients of the study drug or their analogues 5. hiv infection 6. hbv-dna or hcv-rna positive 7. subjects with grade 2 or above cardiac failure and those considered unsuitable for inclusion by the investigator 8. subjects who are pregnant or breastfeeding 9. subjects reject to participate in the study
analgesic efficacy of dexamethasone in different routes of administration in transverse abdominis plane block

Conditions: INFERTILITY

Summary: transverse abdominis plane (tap) block is a regional anaesthesia technique that provides analgesia to the parietal peritoneum as well as skin and muscles of the anterior abdominal wall. in the past, a number of adjuvants have been added to the local anaesthetics in peripheral and neuraxial blocks resulting in an effective and long lasting analgesia.in recent times, dexamethasone has been increasingly used as an adjuvant to local anaesthetics in peripheral nerve blocks. dexamethasone has a long and efficient glucocorticoid structure and also has anti-inflammatory property. it also blocks the c- fibers of pain pathway. when added to local anaesthetics as an adjuvant in peripheral nerve blocks, it has shown to prolong the analgesia time. a number of previous studies have also shown an opioid sparing effect of steroids, when used intravenously perioperatively. though previous studies have shown that addition of dexamethasone to local anaesthetics in transverse abdominis plane block prolongs the duration of block, however it is not known whether this effect of dexamethasone is due to its peripheral action or because of its systemic absorption. thus, in this study planned to compare the effectiveness of dexamethasone on quality and duration of analgesia when used as an adjuvant with local anaesthetics in transverse abdominis plane block versus when given systemically by intravenous route along with transverse abdominis plane block using local anaesthetics only, in patients undergoing gynaecological laparoscopic procedures under general anaesthesia.


Eligibility criteria:
inclusion criteria: 1. women aged between 18 to 70 years undergoing gynaecological laparoscopic surgeries under general anaesthesia 2. asa physical status1 or 2 exclusion criteria: 1. local infection 2. morbid obesity (body mass index \>35kg/m2) 3. allergy to local anaesthetics 4. patient refusal 5. severe respiratory or cardiac disorders 6. pre-existing neurological deficits 7. liver or renal insufficiency 8. preexisting diabetics 9. patient on steroid treatment for any reason. 10. peri operative use of steroids
is access to liver transplantation similar in alcoholic or not patients?

Conditions: Inpatient With End Stage Liver Disease

Summary: the purpose of this study is to determine whether there are reasons other than medical reasons that could limit access to liver transplantation in alcoholic patients.

the investigators perform a study combining the follow up of a previous cohort of 450 patients and the inclusion of 150 new patients. the study is performed in medical or hepatogastroenterology departments of nine french public hospitals mostly non-teaching. they lay in three french area, selected according to the density of patients with alcoholic liver disease (ald) in the area, respectively, "high" as in brittany-loire, 'average' in ile de france and "low" as in the languedoc-roussillon. the patients included in the cohort must respond to the following criteria: having liver cirrhosis of whatever origin and age over 18 years. the cirrhosis must be confirmed by the morphological or histological criteria. structured forms and questionnaires will allow the collection of data. information collected from patients include socio demographic characteristics, medical history, history of consumption of psychotropic (i.e., alcohol or drugs), clinical, biological, histological characteristics and psychological. inpatients complete a self-assessment structured questionnaire "hospital anxiety depression scale" (had). patients are followed until they are registered or not on the national waiting list or die, every 6 months after inclusion until 2 years. statistical analysis will focus on descriptive analysis, survival analysis by kaplan-meier, and analytic analysis. association with registration on the national waiting list of inpatients will be searched using cox and logistic regression models. further analyzes will be conducted for example on the differences of opinion between physicians and patients, on regional differences.

Eligibility criteria:
inclusion criteria: * inpatients * age over 18 * having liver cirrhosis of whatever origin (cirrhosis was confirmed if morphological or histological criteria with or without esophageal varicoses were met) exclusion criteria: * outpatients * age less to 18 * with acute liver failure or hepatocarcinoma without liver cirrhosis

Keywords: inpatient liver cirrhosis liver cirrhosis, alcoholic physician's practice patterns liver transplantation delivery of health care resource allocation
facilitating participation in a prostate cancer risk assessment program

Conditions: Prostate Cancer

Summary: the purpose of this study was to examine whether a cognitive-affective preparation was more beneficial, in general, and more specifically for certain subgroups, such as african-american men and individuals with high monitoring style.

high risk men enrolling in a state of the science prostate cancer risk assessment program (n = 128) underwent a pca counseling visit immediately followed by either a cognitive-affective preparation (cap) session designed to help men process the information they received or a general health education session to control for time and attention (comparison group). all men chose to participate in pca screening.

Eligibility criteria:
inclusion criteria: * caucasian men, 34 and 69 years of age, at least one first or second degree relative with prostate cancer or * african american men, 35 and 69 years of age exclusion criteria: * cancer diagnosis * difficulty communicating in english * impaired competency to give informed consent.

Keywords: cognitive-affective preparation prostate cancer counseling
management and clinical outcomes of patients with severe mitral valve disease not suitable for surgery

Conditions: Mitral Valve Disease

Summary: the objective of this study is to collect in a prospective registry all cases of french patients undergoing an assessment for percutaneous treatment of mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement. in these patients, valvular surgery should be considered contra-indicated or at prohibitive risk. this registry will evaluate the morbidity and mortality up to 24 months for those patients with severe mitral valve disease who are not included in a clinical trial. the association of demographic, clinical, laboratory, echocardiographic variables and treatment options with morbidity and mortality will be evaluated by univariate and multivariate analyses.

patients with symptomatic severe mitral valve disease will have a medical evaluation visit (physical examination, ecg, biology) with transthoracic ± transesophageal echocardiography in each center. if the patient is considered not eligible for surgery by the heart-team and is not included in a clinical trial, the investigator informs the patient of the existence of the registry and verifies that it does not express opposition to the use of its clinical data. in each participating center, demographic information, clinical, laboratory, echocardiographic and treatment options will be collected and reported in an electronic case report form (e-crf). each center will be responsible of patient monitoring, including phone call at 6 months and a medical visit at 1 and 2 years. transthoracic echocardiography will also be performed at 1 year and 2 years.

Eligibility criteria:
* aged over 18 years * presenting with severe mitral valve stenosis or regurgitation regardless of etiology (primary mitral regurgitation, secondary mitral regurgitation, deterioration of mitral valve repair or bioprosthesis, mitral annular calcification) * symptomatic (nyha functional class ii-iv) despite optimized medical therapy * judged not eligible for surgical treatment according to a specialized multidisciplinary meeting called "heart team" comprising at least one cardiothoracic surgeon, one interventional cardiologist, one echocardiographer, one clinical cardiologist and one anaesthesiologist. * having received information about the study and not expressing opposition to the use of their data * patient not included in a clinical trial exclusion criteria: * asymptomatic patients * absence of severe mitral regurgitation or stenosis * patient judged eligible for surgical treatment according to a specialized multidisciplinary meeting called "heart team" comprising at least one cardiothoracic surgeon, one interventional cardiologist, one echocardiographer, one clinical cardiologist and one anaesthesiologist. * pregnant or breastfeeding women * having not received information about the study or having expressed opposition to the use of their data

Keywords: mitral regurgitation mitral stenosis mitral valve repair deterioration bioprosthesis degeneration
effect of age, body mass index and tumor sidedness in metastatic colorectal cancer

Conditions: Colorectal Cancer Metastatic

Summary: to determine progression free survival (pfs) and overall survival (os) in metastatic colorectal cancer in relation to age, bmi and tumor sidedness, describing their predictive influence on systemic therapy outcome.

colorectal cancer (crc) represents a major public health concern as it is the third most frequently diagnosed cancer and the fourth cause of cancer-related mortality worldwide . the ﬁve-year survival rate is around 64.9% for all stages, while in metastatic cases, it only reaches 13.1% . approximately 26% of crcs are diagnosed at stage iv among patients aged younger than 50 years, compared with 23% in those aged 50 to 64 years and 19% among those aged 65 years and older. overall survival (os) among patients younger than 50 years (68%) is similar to that in those 50 to 64 years (69%) because of a later stage at diagnosis. obesity is associated with an increased incidence of crc . in recent studies body mass index (bmi) was prognostic for overall survival and progression free survival. that is risk of progression and/or death was greatest for low bmi; risk decreased as bmi increased. bmi was not predictive of treatment effect . cachexia and associated poor performance status have previously been identiﬁed as negative prognostic factors in patients with crc. tumor sidedness is an independent prognostic factor in patients with early and metastatic crc as left-sided primaries have improved outcomes. sidedness also represents a powerful predictor of benefit from anti epidermal growth factor receptor\[egfr\] inhibitors therapies in patients with ras wild-type metastatic crc (mcrc) . the mainstay of treatment of mcrc includes cytotoxic chemotherapy with the addition of a molecularly targeted agent . the cytotoxic regimens that are usually used include a combination of oxaliplatin or irinotecan with a fluoropyrimidine, in addition to targeted agents such as \[egfr\] inhibitors for patients with ras wild-type mcrc or vascular endothelial growth factor inhibitors .

Eligibility criteria:
inclusion criteria: * age \>18 years. * pathologically proven colon or rectal adenocarcinoma. * stage iv colorectal cancer. exclusion criteria: * age \<18 years. * not pathologically proven colon or rectal adenocarcinoma. * stage i, ii and iii colorectal cancer.
the hospice advanced dementia symptom management and quality of life trial

Conditions: Dementia

Summary: alzheimer's disease and related disorders (dementia) are a group of serious life limiting illness that cause significant challenges to our public health system, with significant illness burden for both the person with dementia and the caregiver. at the end of life, over 230,000 persons with dementia annually are cared for in hospice, yet hospice agencies are ill prepared to care for this population and often resort to inappropriate pharmacologic measures such as antipsychotics that reduce quality of life rather than improve it. this study will therefore through its two phases refine and then implement, using a pragmatic stepped wedge trial design, the dementia symptom management at home program hospice edition, with the goal improving quality of care for the person with dementia and their caregiver, reducing antipsychotic use, and increasing bereaved caregiver satisfaction in the hospice setting.


Eligibility criteria:
inclusion criteria: * must have dementia as primary diagnosis for admission to hospice * must be newly admitted to a participating hospice * must be 50 years or older clinicians: * must be a skilled clinician or home health aide who provides care through an eligible home health agency * must be 18 years or older exclusion criteria: persons with dementia: * none clinicians: * none
efficacy of manuka honey nano-formulation in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: the present study aims to manufacture manuka honey-loaded nano-formulation using natural materials as a potent tissue-healing remedy and compare it to commercially available antimicrobial therapy in order to reduce the severity and recurrences of skin lesions.

it was found that patients with acne suffer from lower self-esteem, depression, anxiety, and social isolation as a result of papules, pustules, nodules, cysts, and scarring. moreover, a common complication of acne is residual post-inflammatory hyperpigmentation and acne scaring which cause further psychological and social distress. collectively, these factors explain the reduction of quality of life . the intervention for av treatment has been unaltered throughout last years. there is a global shift from antibiotics concerning limiting their use due to increasing antibiotic resistance. hence, it is imperative to provide natural products as another modality of treatment. manuka honey (mh) is a mono-floral honey harvested by honeybees (apis mellifera) after pollinating and collecting nectar primarily from the manuka tree. mh's anti-inflammatory and broad-spectrum antibacterial activity is due to its major ingredients, hydrogen peroxide h2o2 produced enzymatically, non-peroxidase methylglyoxal (mgo), and the peptide bee defensin-1 which has antimicrobial action. furthermore, mh inhibits bacterial growth by high osmolality and low ph. a high mgo content mh nano-formulation will be fabricated to serve as a vehicle for its topical delivery.

Eligibility criteria:
inclusion criteria: * mild to moderate acne vulgaris patients.patients will be assessed for severity of acne by global acne grading system (gags). * age of patients: 18-40 years. * sex: both sexes. exclusion criteria: * pregnancy and lactation. * severe acne vulgaris. * exogenous acne as industrial or cosmetic causes. * patients with photodermatitis or allergic dermatitis. * serious or systemic illnesses such as liver and renal dysfunction. * patients with radiotherapy, cryotherapy, cutaneous malignant tumors, and patients suffer from mental illnesses.
the effects of passive heat therapy in patients with chronic kidney disease

Conditions: Renal Insufficiency, Chronic

Summary: the objective of this proposal is to investigate the acute effects of whole-body passive heat therapy using far-infrared technology on vascular function, exercise capacity, and renal function in ckd patients. the central hypothesis is that an acute bout of whole-body passive heat therapy will be well-tolerated and lead to acute improvements in large blood vessel (macrovascular) function, small blood vessel (microvascular) function, and exercise capacity without significantly altering markers of acute kidney injury.


Eligibility criteria:
inclusion criteria for participants with ckd: * age \> 18 years old * stage 2-4 ckd exclusion criteria for participants with ckd: * unstable medical conditions characterized by frequent or unpredictable biological, chemical, or psychological changes * uncontrolled hypertension * current fluid restrictions * end stage kidney disease or currently on dialysis treatment * body weight \< 40kg * exhibits any contraindications to exercise as per acsm guidelines * regular tobacco and/or nicotine use * history of heat-related illness * participates in regular exercise and/or sauna use * current hormone replacement therapy * pacemaker or electro-medical implant * persons with or at risk of intestinal disorders including gastroporesis * history of diverticula * persons who have undergone surgical procedures in the gi tract * swallowing disorders * chron's disease * current pregnancy * inability to provide informed consent
cardiac resynchronization therapy (crt) and left ventricular assist devices (lvad) therapy

Conditions: Heart Failure

Summary: cardiac resynchronization therapy (crt) or biventricular pacing is a useful treatment for heart failure and those suffering from arrhythmias. the purpose of this research study is to determine the effect left-ventricular pacing has on patients who have a ventricular assist device.

as part of the study participation the following two visits will be completed as listed below. baseline visit: the following procedures will be conducted at this visit: * review of past medical history and medical records; * a limited echocardiogram will be performed. this is a test that uses ultrasound to evaluate the size of the heart and how well the heart is pumping blood. * the investigators will use a computer-like device, called a programmer, that "talks" to the crt device using radio signals or by using wanded telemetry to adjust the crt device's programmed settings. the left ventricular lead of your device will be turned off. the defibrillator will continue to function and back-up pacing will continue if needed. * complete the kansas city cardiomyopathy questionnaire (kccq). * a 6 minute walk test will be done. regularly scheduled clinic visit: at the next regularly scheduled left ventricular assist devices (lvad) clinic visit, approximately 4 weeks after the baseline visit, the following procedures will be done: * a second limited echocardiogram. * the investigator will use a computer-like device, called a programmer, that "talks" to the crt device using radio signals or by using a wand to obtain a report that will give the current program settings and any heart rhythm events that have occurred since the last crt device was checked. once the information from the crt is obtained, the study doctor will reprogram the device to its original settings. * complete the kansas city cardiomyopathy questionnaire (kccq). * a 6 minute walk test will be done.

Eligibility criteria:
inclusion criteria: * presence of lvad support and crt device with working lv lead in patients \> 18years of age * left ventricular pacing at time of enrollment exclusion criteria: * lv lead dysfunction * prior av node ablation * presence of total heart block * presence of significant bradycardia/lack of underlying rhythm * inability to complete 6 minute walk test * inability to return to clinic for repeat assessment * any lvad programmed speed change within the prior 30 days * any crt programming changes within the prior 30 days

Keywords: left ventricular assist devices (lvad) cardiac resynchronization devices (crt)
assessment of the emfit mattress sensor for detection and alarm of night-time generalized tonic-clonic seizures.

Conditions: Epilepsy; Seizures

Summary: sudden unexpected death in epilepsy (sudep) is the most important epilepsy-related mode of death. the exact mechanism of sudep is not known. it is thought that cardiac and respiratory factors are involved. several ways of preventing sudep have been identified. these include seizure control, stress reduction, physical activity, family's ability to perform cpr, and night supervision. a mattress alarm system that monitors nocturnal seizures can alert family members of night time seizure activity. thus, a family member could provide aid and therefore potentially avoid sudep. the emfit monitor is intended to perform these tasks. investigators tested the emfit mattress monitor dvm-gprs-v2 in combination with the emfit bed sensor l-4060sl in the epilepsy monitoring unit and were able to demonstrate that the device has a high predictive value for detection of generalized convulsions and that it can notify caregivers in the early stages of convulsive activity. this study will further investigate the upgraded (connected to a cloud server via an integrated cellular gprs module) emfit mattress monitor dvm-gprs-v2 and the upgraded emfit mattress sensor l-4060slc in combination with an acoustic and new cloud-based notification system.


Eligibility criteria:
inclusion criteria: * overnight epilepsy monitoring unit admission exclusion criteria: * 12 hours or shorter epilepsy monitoring unit admission

Keywords: epilepsy seizure seizures mattress monitor bed monitor bed alarm generalized tonic-clonic seizure gtc